NanoViricides President Dr. Diwan to Present at the PODD Conference
NanoViricides, Inc. (NNVC)
NASDAQ:AMEX Investor Relations:
nanoviricides.com/investorinfo.html
Company Research
Source: Accesswire
Impact Snapshot
Event Time:
NNVC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NNVC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NNVC alerts
High impacting NanoViricides, Inc. news events
Weekly update
A roundup of the hottest topics
NNVC
News
- NanoViricides, Inc. (NYSE: NNVC) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond VirologyAccesswire
- NanoViricides to Present at the Global AMR Summit 2024 TomorrowAccesswire
- NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVIDAccesswire
- NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” DrugsAccesswire
NNVC
Sec Filings
- 10/15/24 - Form DEF
- 9/27/24 - Form 10-K
- 8/9/24 - Form 8-K
- NNVC's page on the SEC website